Condition
Myelogenous Leukemia, Chronic, Chronic Phase
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Unknown2
Terminated1
Clinical Trials (3)
Showing 3 of 3 trials
NCT00038649Phase 2TerminatedPrimary
Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C
NCT01887561Phase 2UnknownPrimary
Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial
NCT01464411Unknown
Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan
Showing all 3 trials